The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Low Molecular Weight Nucleic Acid Drugs Market Research Report 2025
Synopsis
The relatively low molecular weight nucleic acid drugs, such as miRNA, ASO, siRNA, aptamers, and ribozymes, could be classified as oligonucleotides that do not express proteins directly. Small Nucleic Acid Drugs utilize nucleic acid, which refer to substances such as DNA and RNA that control genetic information, as drugs. These allow targeting of molecules such as mRNA and miRNA that cannot be targeted with traditional low molecular weight drugs and antibody medicines, and there is a great expectation for these drugs as next generation pharmaceuticals. Active research is being conducted globally as it is expected to lead to the creation of drugs which were previously intractable.
The global Low Molecular Weight Nucleic Acid Drugs market was valued at US$ 87 million in 2023 and is anticipated to reach US$ 129.7 million by 2030, witnessing a CAGR of 5.7% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Low molecular weight nucleic acid drugs have emerged as a burgeoning area of research in the pharmaceutical field in recent years. The market for these drugs is progressively expanding, garnering considerable attention within the pharmaceutical industry. Owing to their unique molecular structure and biological characteristics, such drugs hold significant potential for applications spanning cancer treatment, genetic disorder therapy, antiviral interventions, among others. Despite currently modest market sales, ongoing advancements in research technology and deepening clinical trials are poised to drive substantial breakthroughs and development for low molecular weight nucleic acid drugs in the foreseeable future.
This report aims to provide a comprehensive presentation of the global market for Low Molecular Weight Nucleic Acid Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Low Molecular Weight Nucleic Acid Drugs.
Report Scope
The Low Molecular Weight Nucleic Acid Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Low Molecular Weight Nucleic Acid Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Low Molecular Weight Nucleic Acid Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Ionis
Nippon Shinyaku
Alnylam
Sarepta Therapeutics
MiNA Therapeutics
BioNTech
Moderna
Segment by Type
ASO
siRNA
Other
Segment by Application
Cardiovascular Diseases
Hepatitis B
Hypertension
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Low Molecular Weight Nucleic Acid Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Low Molecular Weight Nucleic Acid Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The relatively low molecular weight nucleic acid drugs, such as miRNA, ASO, siRNA, aptamers, and ribozymes, could be classified as oligonucleotides that do not express proteins directly. Small Nucleic Acid Drugs utilize nucleic acid, which refer to substances such as DNA and RNA that control genetic information, as drugs. These allow targeting of molecules such as mRNA and miRNA that cannot be targeted with traditional low molecular weight drugs and antibody medicines, and there is a great expectation for these drugs as next generation pharmaceuticals. Active research is being conducted globally as it is expected to lead to the creation of drugs which were previously intractable.
The global Low Molecular Weight Nucleic Acid Drugs market was valued at US$ 87 million in 2023 and is anticipated to reach US$ 129.7 million by 2030, witnessing a CAGR of 5.7% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Low molecular weight nucleic acid drugs have emerged as a burgeoning area of research in the pharmaceutical field in recent years. The market for these drugs is progressively expanding, garnering considerable attention within the pharmaceutical industry. Owing to their unique molecular structure and biological characteristics, such drugs hold significant potential for applications spanning cancer treatment, genetic disorder therapy, antiviral interventions, among others. Despite currently modest market sales, ongoing advancements in research technology and deepening clinical trials are poised to drive substantial breakthroughs and development for low molecular weight nucleic acid drugs in the foreseeable future.
This report aims to provide a comprehensive presentation of the global market for Low Molecular Weight Nucleic Acid Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Low Molecular Weight Nucleic Acid Drugs.
Report Scope
The Low Molecular Weight Nucleic Acid Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Low Molecular Weight Nucleic Acid Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Low Molecular Weight Nucleic Acid Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Ionis
Nippon Shinyaku
Alnylam
Sarepta Therapeutics
MiNA Therapeutics
BioNTech
Moderna
Segment by Type
ASO
siRNA
Other
Segment by Application
Cardiovascular Diseases
Hepatitis B
Hypertension
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Low Molecular Weight Nucleic Acid Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Low Molecular Weight Nucleic Acid Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Low Molecular Weight Nucleic Acid Drugs Market Overview
1.1 Product Overview and Scope of Low Molecular Weight Nucleic Acid Drugs
1.2 Low Molecular Weight Nucleic Acid Drugs Segment by Type
1.2.1 Global Low Molecular Weight Nucleic Acid Drugs Market Value Comparison by Type (2024-2030)
1.2.2 ASO
1.2.3 siRNA
1.2.4 Other
1.3 Low Molecular Weight Nucleic Acid Drugs Segment by Application
1.3.1 Global Low Molecular Weight Nucleic Acid Drugs Market Value by Application: (2024-2030)
1.3.2 Cardiovascular Diseases
1.3.3 Hepatitis B
1.3.4 Hypertension
1.3.5 Other
1.4 Global Low Molecular Weight Nucleic Acid Drugs Market Size Estimates and Forecasts
1.4.1 Global Low Molecular Weight Nucleic Acid Drugs Revenue 2019-2030
1.4.2 Global Low Molecular Weight Nucleic Acid Drugs Sales 2019-2030
1.4.3 Global Low Molecular Weight Nucleic Acid Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Low Molecular Weight Nucleic Acid Drugs Market Competition by Manufacturers
2.1 Global Low Molecular Weight Nucleic Acid Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Low Molecular Weight Nucleic Acid Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Low Molecular Weight Nucleic Acid Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Low Molecular Weight Nucleic Acid Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Low Molecular Weight Nucleic Acid Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Low Molecular Weight Nucleic Acid Drugs, Product Type & Application
2.7 Low Molecular Weight Nucleic Acid Drugs Market Competitive Situation and Trends
2.7.1 Low Molecular Weight Nucleic Acid Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Low Molecular Weight Nucleic Acid Drugs Players Market Share by Revenue
2.7.3 Global Low Molecular Weight Nucleic Acid Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Low Molecular Weight Nucleic Acid Drugs Retrospective Market Scenario by Region
3.1 Global Low Molecular Weight Nucleic Acid Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Low Molecular Weight Nucleic Acid Drugs Global Low Molecular Weight Nucleic Acid Drugs Sales by Region: 2019-2030
3.2.1 Global Low Molecular Weight Nucleic Acid Drugs Sales by Region: 2019-2024
3.2.2 Global Low Molecular Weight Nucleic Acid Drugs Sales by Region: 2025-2030
3.3 Global Low Molecular Weight Nucleic Acid Drugs Global Low Molecular Weight Nucleic Acid Drugs Revenue by Region: 2019-2030
3.3.1 Global Low Molecular Weight Nucleic Acid Drugs Revenue by Region: 2019-2024
3.3.2 Global Low Molecular Weight Nucleic Acid Drugs Revenue by Region: 2025-2030
3.4 North America Low Molecular Weight Nucleic Acid Drugs Market Facts & Figures by Country
3.4.1 North America Low Molecular Weight Nucleic Acid Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Low Molecular Weight Nucleic Acid Drugs Sales by Country (2019-2030)
3.4.3 North America Low Molecular Weight Nucleic Acid Drugs Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Low Molecular Weight Nucleic Acid Drugs Market Facts & Figures by Country
3.5.1 Europe Low Molecular Weight Nucleic Acid Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Low Molecular Weight Nucleic Acid Drugs Sales by Country (2019-2030)
3.5.3 Europe Low Molecular Weight Nucleic Acid Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Low Molecular Weight Nucleic Acid Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Low Molecular Weight Nucleic Acid Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Low Molecular Weight Nucleic Acid Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Low Molecular Weight Nucleic Acid Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Low Molecular Weight Nucleic Acid Drugs Market Facts & Figures by Country
3.7.1 Latin America Low Molecular Weight Nucleic Acid Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Low Molecular Weight Nucleic Acid Drugs Sales by Country (2019-2030)
3.7.3 Latin America Low Molecular Weight Nucleic Acid Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Low Molecular Weight Nucleic Acid Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Low Molecular Weight Nucleic Acid Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Low Molecular Weight Nucleic Acid Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Low Molecular Weight Nucleic Acid Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Low Molecular Weight Nucleic Acid Drugs Sales by Type (2019-2030)
4.1.1 Global Low Molecular Weight Nucleic Acid Drugs Sales by Type (2019-2024)
4.1.2 Global Low Molecular Weight Nucleic Acid Drugs Sales by Type (2025-2030)
4.1.3 Global Low Molecular Weight Nucleic Acid Drugs Sales Market Share by Type (2019-2030)
4.2 Global Low Molecular Weight Nucleic Acid Drugs Revenue by Type (2019-2030)
4.2.1 Global Low Molecular Weight Nucleic Acid Drugs Revenue by Type (2019-2024)
4.2.2 Global Low Molecular Weight Nucleic Acid Drugs Revenue by Type (2025-2030)
4.2.3 Global Low Molecular Weight Nucleic Acid Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Low Molecular Weight Nucleic Acid Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Low Molecular Weight Nucleic Acid Drugs Sales by Application (2019-2030)
5.1.1 Global Low Molecular Weight Nucleic Acid Drugs Sales by Application (2019-2024)
5.1.2 Global Low Molecular Weight Nucleic Acid Drugs Sales by Application (2025-2030)
5.1.3 Global Low Molecular Weight Nucleic Acid Drugs Sales Market Share by Application (2019-2030)
5.2 Global Low Molecular Weight Nucleic Acid Drugs Revenue by Application (2019-2030)
5.2.1 Global Low Molecular Weight Nucleic Acid Drugs Revenue by Application (2019-2024)
5.2.2 Global Low Molecular Weight Nucleic Acid Drugs Revenue by Application (2025-2030)
5.2.3 Global Low Molecular Weight Nucleic Acid Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Low Molecular Weight Nucleic Acid Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Corporation Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Low Molecular Weight Nucleic Acid Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novartis Low Molecular Weight Nucleic Acid Drugs Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Ionis
6.2.1 Ionis Corporation Information
6.2.2 Ionis Description and Business Overview
6.2.3 Ionis Low Molecular Weight Nucleic Acid Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Ionis Low Molecular Weight Nucleic Acid Drugs Product Portfolio
6.2.5 Ionis Recent Developments/Updates
6.3 Nippon Shinyaku
6.3.1 Nippon Shinyaku Corporation Information
6.3.2 Nippon Shinyaku Description and Business Overview
6.3.3 Nippon Shinyaku Low Molecular Weight Nucleic Acid Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Nippon Shinyaku Low Molecular Weight Nucleic Acid Drugs Product Portfolio
6.3.5 Nippon Shinyaku Recent Developments/Updates
6.4 Alnylam
6.4.1 Alnylam Corporation Information
6.4.2 Alnylam Description and Business Overview
6.4.3 Alnylam Low Molecular Weight Nucleic Acid Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Alnylam Low Molecular Weight Nucleic Acid Drugs Product Portfolio
6.4.5 Alnylam Recent Developments/Updates
6.5 Sarepta Therapeutics
6.5.1 Sarepta Therapeutics Corporation Information
6.5.2 Sarepta Therapeutics Description and Business Overview
6.5.3 Sarepta Therapeutics Low Molecular Weight Nucleic Acid Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Sarepta Therapeutics Low Molecular Weight Nucleic Acid Drugs Product Portfolio
6.5.5 Sarepta Therapeutics Recent Developments/Updates
6.6 MiNA Therapeutics
6.6.1 MiNA Therapeutics Corporation Information
6.6.2 MiNA Therapeutics Description and Business Overview
6.6.3 MiNA Therapeutics Low Molecular Weight Nucleic Acid Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 MiNA Therapeutics Low Molecular Weight Nucleic Acid Drugs Product Portfolio
6.6.5 MiNA Therapeutics Recent Developments/Updates
6.7 BioNTech
6.6.1 BioNTech Corporation Information
6.6.2 BioNTech Description and Business Overview
6.6.3 BioNTech Low Molecular Weight Nucleic Acid Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 BioNTech Low Molecular Weight Nucleic Acid Drugs Product Portfolio
6.7.5 BioNTech Recent Developments/Updates
6.8 Moderna
6.8.1 Moderna Corporation Information
6.8.2 Moderna Description and Business Overview
6.8.3 Moderna Low Molecular Weight Nucleic Acid Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Moderna Low Molecular Weight Nucleic Acid Drugs Product Portfolio
6.8.5 Moderna Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Low Molecular Weight Nucleic Acid Drugs Industry Chain Analysis
7.2 Low Molecular Weight Nucleic Acid Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Low Molecular Weight Nucleic Acid Drugs Production Mode & Process
7.4 Low Molecular Weight Nucleic Acid Drugs Sales and Marketing
7.4.1 Low Molecular Weight Nucleic Acid Drugs Sales Channels
7.4.2 Low Molecular Weight Nucleic Acid Drugs Distributors
7.5 Low Molecular Weight Nucleic Acid Drugs Customers
8 Low Molecular Weight Nucleic Acid Drugs Market Dynamics
8.1 Low Molecular Weight Nucleic Acid Drugs Industry Trends
8.2 Low Molecular Weight Nucleic Acid Drugs Market Drivers
8.3 Low Molecular Weight Nucleic Acid Drugs Market Challenges
8.4 Low Molecular Weight Nucleic Acid Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Low Molecular Weight Nucleic Acid Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Low Molecular Weight Nucleic Acid Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Low Molecular Weight Nucleic Acid Drugs Market Competitive Situation by Manufacturers in 2023
Table 4. Global Low Molecular Weight Nucleic Acid Drugs Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Low Molecular Weight Nucleic Acid Drugs Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Low Molecular Weight Nucleic Acid Drugs Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Low Molecular Weight Nucleic Acid Drugs Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Low Molecular Weight Nucleic Acid Drugs Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Low Molecular Weight Nucleic Acid Drugs, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Low Molecular Weight Nucleic Acid Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Low Molecular Weight Nucleic Acid Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Low Molecular Weight Nucleic Acid Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Low Molecular Weight Nucleic Acid Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Low Molecular Weight Nucleic Acid Drugs as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Low Molecular Weight Nucleic Acid Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Low Molecular Weight Nucleic Acid Drugs Sales by Region (2019-2024) & (K Units)
Table 18. Global Low Molecular Weight Nucleic Acid Drugs Sales Market Share by Region (2019-2024)
Table 19. Global Low Molecular Weight Nucleic Acid Drugs Sales by Region (2025-2030) & (K Units)
Table 20. Global Low Molecular Weight Nucleic Acid Drugs Sales Market Share by Region (2025-2030)
Table 21. Global Low Molecular Weight Nucleic Acid Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Low Molecular Weight Nucleic Acid Drugs Revenue Market Share by Region (2019-2024)
Table 23. Global Low Molecular Weight Nucleic Acid Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Low Molecular Weight Nucleic Acid Drugs Revenue Market Share by Region (2025-2030)
Table 25. North America Low Molecular Weight Nucleic Acid Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Low Molecular Weight Nucleic Acid Drugs Sales by Country (2019-2024) & (K Units)
Table 27. North America Low Molecular Weight Nucleic Acid Drugs Sales by Country (2025-2030) & (K Units)
Table 28. North America Low Molecular Weight Nucleic Acid Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Low Molecular Weight Nucleic Acid Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Low Molecular Weight Nucleic Acid Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Low Molecular Weight Nucleic Acid Drugs Sales by Country (2019-2024) & (K Units)
Table 32. Europe Low Molecular Weight Nucleic Acid Drugs Sales by Country (2025-2030) & (K Units)
Table 33. Europe Low Molecular Weight Nucleic Acid Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Low Molecular Weight Nucleic Acid Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Low Molecular Weight Nucleic Acid Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Low Molecular Weight Nucleic Acid Drugs Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Low Molecular Weight Nucleic Acid Drugs Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Low Molecular Weight Nucleic Acid Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Low Molecular Weight Nucleic Acid Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Low Molecular Weight Nucleic Acid Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Low Molecular Weight Nucleic Acid Drugs Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Low Molecular Weight Nucleic Acid Drugs Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Low Molecular Weight Nucleic Acid Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Low Molecular Weight Nucleic Acid Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Low Molecular Weight Nucleic Acid Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Low Molecular Weight Nucleic Acid Drugs Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Low Molecular Weight Nucleic Acid Drugs Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Low Molecular Weight Nucleic Acid Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Low Molecular Weight Nucleic Acid Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Low Molecular Weight Nucleic Acid Drugs Sales (K Units) by Type (2019-2024)
Table 51. Global Low Molecular Weight Nucleic Acid Drugs Sales (K Units) by Type (2025-2030)
Table 52. Global Low Molecular Weight Nucleic Acid Drugs Sales Market Share by Type (2019-2024)
Table 53. Global Low Molecular Weight Nucleic Acid Drugs Sales Market Share by Type (2025-2030)
Table 54. Global Low Molecular Weight Nucleic Acid Drugs Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Low Molecular Weight Nucleic Acid Drugs Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Low Molecular Weight Nucleic Acid Drugs Revenue Market Share by Type (2019-2024)
Table 57. Global Low Molecular Weight Nucleic Acid Drugs Revenue Market Share by Type (2025-2030)
Table 58. Global Low Molecular Weight Nucleic Acid Drugs Price (US$/Unit) by Type (2019-2024)
Table 59. Global Low Molecular Weight Nucleic Acid Drugs Price (US$/Unit) by Type (2025-2030)
Table 60. Global Low Molecular Weight Nucleic Acid Drugs Sales (K Units) by Application (2019-2024)
Table 61. Global Low Molecular Weight Nucleic Acid Drugs Sales (K Units) by Application (2025-2030)
Table 62. Global Low Molecular Weight Nucleic Acid Drugs Sales Market Share by Application (2019-2024)
Table 63. Global Low Molecular Weight Nucleic Acid Drugs Sales Market Share by Application (2025-2030)
Table 64. Global Low Molecular Weight Nucleic Acid Drugs Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Low Molecular Weight Nucleic Acid Drugs Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Low Molecular Weight Nucleic Acid Drugs Revenue Market Share by Application (2019-2024)
Table 67. Global Low Molecular Weight Nucleic Acid Drugs Revenue Market Share by Application (2025-2030)
Table 68. Global Low Molecular Weight Nucleic Acid Drugs Price (US$/Unit) by Application (2019-2024)
Table 69. Global Low Molecular Weight Nucleic Acid Drugs Price (US$/Unit) by Application (2025-2030)
Table 70. Novartis Corporation Information
Table 71. Novartis Description and Business Overview
Table 72. Novartis Low Molecular Weight Nucleic Acid Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Novartis Low Molecular Weight Nucleic Acid Drugs Product
Table 74. Novartis Recent Developments/Updates
Table 75. Ionis Corporation Information
Table 76. Ionis Description and Business Overview
Table 77. Ionis Low Molecular Weight Nucleic Acid Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Ionis Low Molecular Weight Nucleic Acid Drugs Product
Table 79. Ionis Recent Developments/Updates
Table 80. Nippon Shinyaku Corporation Information
Table 81. Nippon Shinyaku Description and Business Overview
Table 82. Nippon Shinyaku Low Molecular Weight Nucleic Acid Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Nippon Shinyaku Low Molecular Weight Nucleic Acid Drugs Product
Table 84. Nippon Shinyaku Recent Developments/Updates
Table 85. Alnylam Corporation Information
Table 86. Alnylam Description and Business Overview
Table 87. Alnylam Low Molecular Weight Nucleic Acid Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Alnylam Low Molecular Weight Nucleic Acid Drugs Product
Table 89. Alnylam Recent Developments/Updates
Table 90. Sarepta Therapeutics Corporation Information
Table 91. Sarepta Therapeutics Description and Business Overview
Table 92. Sarepta Therapeutics Low Molecular Weight Nucleic Acid Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Sarepta Therapeutics Low Molecular Weight Nucleic Acid Drugs Product
Table 94. Sarepta Therapeutics Recent Developments/Updates
Table 95. MiNA Therapeutics Corporation Information
Table 96. MiNA Therapeutics Description and Business Overview
Table 97. MiNA Therapeutics Low Molecular Weight Nucleic Acid Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. MiNA Therapeutics Low Molecular Weight Nucleic Acid Drugs Product
Table 99. MiNA Therapeutics Recent Developments/Updates
Table 100. BioNTech Corporation Information
Table 101. BioNTech Description and Business Overview
Table 102. BioNTech Low Molecular Weight Nucleic Acid Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. BioNTech Low Molecular Weight Nucleic Acid Drugs Product
Table 104. BioNTech Recent Developments/Updates
Table 105. Moderna Corporation Information
Table 106. Moderna Description and Business Overview
Table 107. Moderna Low Molecular Weight Nucleic Acid Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Moderna Low Molecular Weight Nucleic Acid Drugs Product
Table 109. Moderna Recent Developments/Updates
Table 110. Key Raw Materials Lists
Table 111. Raw Materials Key Suppliers Lists
Table 112. Low Molecular Weight Nucleic Acid Drugs Distributors List
Table 113. Low Molecular Weight Nucleic Acid Drugs Customers List
Table 114. Low Molecular Weight Nucleic Acid Drugs Market Trends
Table 115. Low Molecular Weight Nucleic Acid Drugs Market Drivers
Table 116. Low Molecular Weight Nucleic Acid Drugs Market Challenges
Table 117. Low Molecular Weight Nucleic Acid Drugs Market Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Low Molecular Weight Nucleic Acid Drugs
Figure 2. Global Low Molecular Weight Nucleic Acid Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Low Molecular Weight Nucleic Acid Drugs Market Share by Type in 2023 & 2030
Figure 4. ASO Product Picture
Figure 5. siRNA Product Picture
Figure 6. Other Product Picture
Figure 7. Global Low Molecular Weight Nucleic Acid Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Low Molecular Weight Nucleic Acid Drugs Market Share by Application in 2023 & 2030
Figure 9. Cardiovascular Diseases
Figure 10. Hepatitis B
Figure 11. Hypertension
Figure 12. Other
Figure 13. Global Low Molecular Weight Nucleic Acid Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Low Molecular Weight Nucleic Acid Drugs Market Size (2019-2030) & (US$ Million)
Figure 15. Global Low Molecular Weight Nucleic Acid Drugs Sales (2019-2030) & (K Units)
Figure 16. Global Low Molecular Weight Nucleic Acid Drugs Average Price (US$/Unit) & (2019-2030)
Figure 17. Low Molecular Weight Nucleic Acid Drugs Report Years Considered
Figure 18. Low Molecular Weight Nucleic Acid Drugs Sales Share by Manufacturers in 2023
Figure 19. Global Low Molecular Weight Nucleic Acid Drugs Revenue Share by Manufacturers in 2023
Figure 20. The Global 5 and 10 Largest Low Molecular Weight Nucleic Acid Drugs Players: Market Share by Revenue in 2023
Figure 21. Low Molecular Weight Nucleic Acid Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 22. Global Low Molecular Weight Nucleic Acid Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 23. North America Low Molecular Weight Nucleic Acid Drugs Sales Market Share by Country (2019-2030)
Figure 24. North America Low Molecular Weight Nucleic Acid Drugs Revenue Market Share by Country (2019-2030)
Figure 25. United States Low Molecular Weight Nucleic Acid Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Canada Low Molecular Weight Nucleic Acid Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. Europe Low Molecular Weight Nucleic Acid Drugs Sales Market Share by Country (2019-2030)
Figure 28. Europe Low Molecular Weight Nucleic Acid Drugs Revenue Market Share by Country (2019-2030)
Figure 29. Germany Low Molecular Weight Nucleic Acid Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. France Low Molecular Weight Nucleic Acid Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. U.K. Low Molecular Weight Nucleic Acid Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Italy Low Molecular Weight Nucleic Acid Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Russia Low Molecular Weight Nucleic Acid Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Asia Pacific Low Molecular Weight Nucleic Acid Drugs Sales Market Share by Region (2019-2030)
Figure 35. Asia Pacific Low Molecular Weight Nucleic Acid Drugs Revenue Market Share by Region (2019-2030)
Figure 36. China Low Molecular Weight Nucleic Acid Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Japan Low Molecular Weight Nucleic Acid Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. South Korea Low Molecular Weight Nucleic Acid Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. India Low Molecular Weight Nucleic Acid Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Australia Low Molecular Weight Nucleic Acid Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. China Taiwan Low Molecular Weight Nucleic Acid Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Southeast Asia Low Molecular Weight Nucleic Acid Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Latin America Low Molecular Weight Nucleic Acid Drugs Sales Market Share by Country (2019-2030)
Figure 44. Latin America Low Molecular Weight Nucleic Acid Drugs Revenue Market Share by Country (2019-2030)
Figure 45. Mexico Low Molecular Weight Nucleic Acid Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Brazil Low Molecular Weight Nucleic Acid Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Argentina Low Molecular Weight Nucleic Acid Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa Low Molecular Weight Nucleic Acid Drugs Sales Market Share by Country (2019-2030)
Figure 49. Middle East & Africa Low Molecular Weight Nucleic Acid Drugs Revenue Market Share by Country (2019-2030)
Figure 50. Turkey Low Molecular Weight Nucleic Acid Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Saudi Arabia Low Molecular Weight Nucleic Acid Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. UAE Low Molecular Weight Nucleic Acid Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Global Sales Market Share of Low Molecular Weight Nucleic Acid Drugs by Type (2019-2030)
Figure 54. Global Revenue Market Share of Low Molecular Weight Nucleic Acid Drugs by Type (2019-2030)
Figure 55. Global Low Molecular Weight Nucleic Acid Drugs Price (US$/Unit) by Type (2019-2030)
Figure 56. Global Sales Market Share of Low Molecular Weight Nucleic Acid Drugs by Application (2019-2030)
Figure 57. Global Revenue Market Share of Low Molecular Weight Nucleic Acid Drugs by Application (2019-2030)
Figure 58. Global Low Molecular Weight Nucleic Acid Drugs Price (US$/Unit) by Application (2019-2030)
Figure 59. Low Molecular Weight Nucleic Acid Drugs Value Chain
Figure 60. Low Molecular Weight Nucleic Acid Drugs Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
